logo

Esperion Therapeutics (ESPR)



Trade ESPR now with
  Date
  Headline
1/13/2021 6:30:25 AM Esperion Sees Q4 Preliminary Net U.S. Product Sales To Be Between $8.0 Mln And $8.5 Mln
12/16/2020 3:20:44 AM Daiichi Sankyo, Esperion Therapeutics Announce Swissmedic Approval For NILEMDO Tablet And NUSTENDI Tablet
11/13/2020 9:33:28 AM Esperion Presents Results Of Pooled Data From Four Of Phase 3 Trials At AHA 2020
11/10/2020 4:59:29 PM Esperion Plans Private Offering Of $200.0 Mln Of Convertible Senior Subordinated Notes
6/22/2020 7:10:50 AM Esperion Completes Amendment To EU Commercial Collaboration Agreement With Daiichi Sankyo Europe
6/14/2020 12:07:21 PM Esperion Announces Pooled Analysis From Phase 3 LDL-C Lowering Clinical Development Program Of NEXLETOL Tablets
6/4/2020 7:10:10 AM Esperion Reports Commercial Availability Of NEXLIZET Tablets
4/20/2020 7:26:21 AM Esperion Agrees With Otsuka Pharma For Commercialization Of NEXLETOL And NEXLIZET Tablets In Japan
4/6/2020 7:14:25 AM Esperion Says European Commission Approves NUSTENDI Tablet For Hypercholesterolemia And Dyslipidemia
3/18/2020 7:31:58 AM Esperion Names Alan Fuhrman To Board Of Directors
11/7/2017 3:36:17 PM Jefferies Is Increasing Esperion Therapeutics (ESPR) FY18 Estimate To -8.54 From -9.36
11/7/2017 3:35:58 PM Jefferies Is Increasing Esperion Therapeutics (ESPR) FY17 Estimate To -7.43 From -7.45
2/23/2017 6:51:29 AM RBC Capital Markets Is Cutting Esperion Therapeutics (ESPR) 2018 Estimate To -6.29 From -4.72